{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:30:19Z","timestamp":1788985819592,"version":"build-2803163510"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Siglecs are sialic acid-binding immunoglobulin-like receptors that regulate immune responses through inhibitory and activating signaling pathways. By recognizing sialoglycan ligands, they modulate innate and adaptive immunity, and their dysregulation is increasingly linked to diverse human diseases. This review highlights the roles of human Siglecs in disease pathogenesis, including cancer, autoimmune and inflammatory disorders, neurodegeneration, and infections. We summarize key regulatory mechanisms such as transcription factors, microRNAs, and protein interactions and outline major signaling pathways underlying Siglec-mediated immune modulation. At the molecular level, Siglecs signal via ITIM dependent inhibitory pathways SHP-1\/SHP-2 or ITAM\/DAP12-associated activation SYK\/MAPK, maintaining immune homeostasis. Targeting the Siglec glycan axis offers promising therapeutic opportunities.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1826359","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:14Z","timestamp":1779342194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunological and pathological roles of Siglecs: a molecular review"],"prefix":"10.3389","volume":"17","author":[{"given":"Lakshmi","family":"K","sequence":"first","affiliation":[{"name":"Integrative Multiomics Lab, Department of Bio Sciences, School of Bio Sciences and Technology, Vellore Institute of Technology","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vino","family":"Sundararajan","sequence":"additional","affiliation":[{"name":"Integrative Multiomics Lab, Department of Bio Sciences, School of Bio Sciences and Technology, Vellore Institute of Technology","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"L\u00e4ubli","year":"2020","journal-title":"Cell Mol Life sciences:CMLS"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.synbio.2023.06.009","article-title":"Recent advances on N-acetylneuraminic acid: Physiological roles, applications, and biosynthesis","volume":"8","author":"Zhao","year":"2023","journal-title":"Synthetic Syst Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075018","article-title":"Siglecs and immune regulation","volume":"30","author":"Pillai","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jfma.2019.10.019","article-title":"Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers","author":"Lin","year":"2021","journal-title":"J Formosan Med Association 120(1"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790317","article-title":"Siglec signaling in the tumor microenvironment","volume":"12","author":"van Houtum","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201695581","article-title":"Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen","volume":"36","author":"Schwarz","year":"2017","journal-title":"EMBO J"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020289","article-title":"The potential of Siglecs and sialic acids as biomarkers and therapeutic targets in tumor immunotherapy","volume":"16","author":"Feng","year":"2024","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104354","article-title":"Inhibitory Siglec\u2013sialic acid interactions in balancing immunological activation and tolerance during viral infections","volume":"86","author":"Saini","year":"2022","journal-title":"eBioMedicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/biology10111178","article-title":"Siglecs as Therapeutic Targets in Cancer","volume":"10","author":"Lim","year":"2021","journal-title":"Biology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12543","article-title":"Siglec-9 is upregulated in rheumatoid arthritis and suppresses collagen-induced arthritis through reciprocal regulation of Th17-\/Treg-cell differentiation","volume":"85","author":"Wang","year":"2017","journal-title":"Scandinavian J Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1038\/s41598-021-89786-0","article-title":"SIGLEC1 (CD169): A marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients","volume":"11","author":"Ostendorf","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.05.061","article-title":"Sensing the neuronal glycocalyx by glial sialic acid\u2013binding immunoglobulin-like lectins","volume":"275","author":"Linnartz-Gerlach","year":"2014","journal-title":"Neuroscience"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101117","article-title":"Discovery, classification, evolution and diversity of Siglecs","volume":"90","author":"Angata","year":"2023","journal-title":"Mol aspects Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1311-7","article-title":"Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation","volume":"70","author":"Angata","year":"2013","journal-title":"Cell Mol Life sciences: CMLS"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490505","article-title":"Siglec15 in blood system diseases: from bench to bedside","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178637","article-title":"Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric Cancer","volume":"26","author":"Cozac-Sz\u0151ke","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-24-01195","article-title":"Polysialic acid\u2013Siglec immune checkpoints of microglia and macrophages: Perspectives for therapeutic intervention","volume":"21","author":"Thiesler","year":"2026","journal-title":"Neural Regeneration Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101893","article-title":"Sialic acid and Siglec receptors in tumor immunity and immunotherapy","author":"Mantuano","year":"2024","journal-title":"Semin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad517","article-title":"The sialic acid\u2013Siglec immune checkpoint: An opportunity to enhance immune responses and therapy effectiveness in melanoma","volume":"190","author":"Coccimiglio","year":"2024","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.11.009","article-title":"Targeting myeloid cells for cancer immunotherapy: Siglec-7\/9\/10\/15 and their ligands","volume":"10","author":"Boelaars","year":"2024","journal-title":"Trends Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2925","article-title":"Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy","volume":"27","author":"Sun","year":"2021","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","article-title":"Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2","volume":"21","author":"Wieboldt","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115774","article-title":"Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments","volume":"22","author":"Gianchecchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwu067","article-title":"The interplay between Siglecs and sialylated pathogens","volume":"24","author":"Chang","year":"2014","journal-title":"Glycobiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2020.01.009","article-title":"Siglec-10 expression is up-regulated in activated human CD4+ T cells","volume":"81","author":"Bandala-Sanchez","year":"2020","journal-title":"Hum Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101887","article-title":"Siglecs as modulators of macrophage phenotype and function","volume":"73","author":"Kukan","year":"2024","journal-title":"Semin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.55730\/1300-0144.5804","article-title":"Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus","volume":"54","author":"Mirio\u011flu","year":"2024","journal-title":"Turkish J Med Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103243","article-title":"Elevated unphosphorylated STAT1 and IRF9 in T and B cells of primary Sj\u00f6gren\u2019s syndrome: Novel biomarkers for disease activity and subsets","volume":"147","author":"Ritter","year":"2024","journal-title":"J Autoimmun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06098-4","article-title":"A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with recent-onset type 1 diabetes","volume":"67","author":"Guo","year":"2024","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e14736","DOI":"10.1111\/cns.14736","article-title":"CD22 blockade aggravates EAE and its role in microglia polarization","volume":"30","author":"Xiang","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382320","article-title":"B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis","volume":"15","author":"Okuzono","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2023.02.007","article-title":"Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy","volume":"255","author":"Liu","year":"2023","journal-title":"Immunol Lett"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.bj.2020.07.007","article-title":"A CD33 frameshift variant is associated with neuromyelitis optica spectrum disorders","author":"Huang","year":"2021","journal-title":"Biomed Journal 44(6"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.160","article-title":"Siglec genes confer resistance to systemic lupus erythematosus in humans and mice","volume":"16","author":"Flores","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101140","article-title":"Impact of Siglecs on autoimmune diseases","volume":"90","author":"Brzezicka","year":"2023","journal-title":"Mol aspects Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cmet.2022.07.005","article-title":"CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cws139","article-title":"The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-\u03b2 secretion from monocytes\/macrophages through the DAP12-Syk pathway","volume":"23","author":"Takamiya","year":"2013","journal-title":"Glycobiology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.107108","article-title":"Siglec-1\u207a macrophages in anti-tumor immunity","volume":"277","author":"Mauvais","year":"2026","journal-title":"Immunol Lett"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1237738","article-title":"Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations","volume":"14","author":"Rubinstein","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17960","article-title":"Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","article-title":"Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1012351","DOI":"10.1371\/journal.ppat.1012351","article-title":"Characterising plasmacytoid and myeloid AXL+ SIGLEC-6+ dendritic cell functions and their interactions with HIV","volume":"20","author":"Warner van Dijk","year":"2024","journal-title":"PloS Pathog"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1038\/s41467-024-48678-3","article-title":"Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia","volume":"15","author":"Nunes","year":"2024","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110157","article-title":"Fusobacterium nucleatum subsp. nucleatum RadD binds Siglec-7 and inhibits NK cell\u2013mediated cancer cell killing","volume":"27","author":"Galaski","year":"2024","journal-title":"iScience"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0823","article-title":"Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells","volume":"12","author":"Eisenberg","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13000-024-01536-8","article-title":"Prognostic and immune infiltration implications of SIGLEC9 in SKCM","volume":"19","author":"Yang","year":"2024","journal-title":"Diagn Pathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S0969","DOI":"10.1016\/j.str.2026.01.018","article-title":"Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10","author":"Medina","year":"2026","journal-title":"Structure (London Engl"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2026.101139","article-title":"CRISPR activation screens map the genomic landscape of cancer glycome remodeling","volume":"6","author":"Daly","year":"2026","journal-title":"Cell Genomics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-25-0977","article-title":"Targeting Interactions Between Siglec-10 and \u03b13\u03b21 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer","volume":"86","author":"Saini","year":"2026","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367959","article-title":"Checkpoint CD24 function on tumor and immunotherapy","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15212\/bioi-2023-0022","article-title":"Targeting the CD24\u2013Siglec-10 axis: A potential strategy for cancer immunotherapy","volume":"5","author":"Fang","year":"2024","journal-title":"Bio Integration"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e181539","DOI":"10.1172\/jci.insight.181539","article-title":"Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers","author":"Cuello","year":"2024","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12545","article-title":"Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine\/Siglec-15 axis in immune escape","volume":"44","author":"Zhang","year":"2024","journal-title":"Cancer Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e13772","DOI":"10.1111\/crj.13772","article-title":"The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma","volume":"18","author":"Sun","year":"2024","journal-title":"Clin Respir J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1330874","article-title":"Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases","volume":"15","author":"Wi\u00dffeld","year":"2024","journal-title":"Front Neurol"},{"key":"B58","author":"Bu","year":"2022"},{"key":"B59","doi-asserted-by":"publisher","first-page":"eabg2919","DOI":"10.1126\/scitranslmed.abg2919","article-title":"The CD22\u2013IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann\u2013Pick type C","volume":"13","author":"Pluvinage","year":"2021","journal-title":"Sci Trans Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.4c00864","article-title":"Structure of the CD33 Receptor and Implications for the Siglec Family","volume":"64","author":"Vu","year":"2025","journal-title":"Biochemistry"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101960","article-title":"Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease","volume":"298","author":"Gonzalez-Gil","year":"2022","journal-title":"J Biol Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.979373","article-title":"Myeloid CD169\/Siglec1: An immunoregulatory biomarker in viral disease","volume":"9","author":"Herzog","year":"2022","journal-title":"Front Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e141965","DOI":"10.1172\/JCI141965","article-title":"SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection","volume":"131","author":"Tsai","year":"2021","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00119-24","article-title":"Neisseria gonorrhoeae scavenges host sialic acid for Siglec-mediated, complement-independent suppression of neutrophil activation","volume":"15","author":"Cardenas","year":"2024","journal-title":"mBio"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01606-9","article-title":"CD169\/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity","volume":"49","author":"Doehn","year":"2021","journal-title":"Infection"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1010479","DOI":"10.1371\/journal.ppat.1010479","article-title":"CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses","volume":"18","author":"Jalloh","year":"2022","journal-title":"PloS Pathog"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1094644","article-title":"Relevance of TMPRSS2, CD163\/CD206, and CD33 in clinical severity stratification of COVID-19","volume":"13","author":"Mart\u00ednez-Diz","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840388","article-title":"Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells","volume":"13","author":"Chang","year":"2022","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650331","article-title":"Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody","volume":"12","author":"Gebremeskel","year":"2021","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0339322","DOI":"10.1128\/mbio.03393-22","article-title":"Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2","volume":"14","author":"Saini","year":"2023","journal-title":"mBio"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c01669","article-title":"Synthetic Siglec-9 agonists inhibit neutrophil activation associated with COVID-19","volume":"7","author":"Delaveris","year":"2021","journal-title":"ACS Cent Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01776-2","article-title":"The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis","volume":"25","author":"He","year":"2024","journal-title":"Nat Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1520","DOI":"10.1002\/cti2.1520","article-title":"Siglec-1, an easy and contributory inflammation marker in rheumatology","volume":"13","author":"Boz","year":"2024","journal-title":"Clin Trans Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket342","article-title":"Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis","volume":"53","author":"Xiong","year":"2014","journal-title":"Rheumatology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology"},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101198","article-title":"SIGLEC-1 in systemic sclerosis: A useful biomarker for differential diagnosis","volume":"15","author":"H\u00f6ppner","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.108","article-title":"Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27","volume":"25","author":"Zheng","year":"2015","journal-title":"Cell Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15327","article-title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","volume":"158","author":"Butler","year":"2021","journal-title":"J Neurochemistry"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: A regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/iji.12489","article-title":"Association of CD33 rs3865444:C\u02c3A polymorphism with a reduced risk of late-onset Alzheimer's disease in Slovaks is limited to subjects carrying the APOE \u03f54 allele","volume":"47","author":"Javor","year":"2020","journal-title":"Int J Immunogenet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141965","article-title":"SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection","volume":"131","author":"Tsung-Yu","year":"2021","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.613195","article-title":"Novel virulence role of pneumococcal NanA in host inflammation and cell death through the activation of inflammasome and the caspase pathway","volume":"11","author":"Tseng","year":"2021","journal-title":"Front Cell Infection Microbiol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996746","article-title":"Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities","volume":"13","author":"Haas","year":"2022","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010019","article-title":"Discovery, Function, and Therapeutic Targeting of Siglec-8","volume":"10","author":"Youngblood","year":"2021","journal-title":"Cells"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response","volume":"4","author":"Mei","year":"2023","journal-title":"Nat Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101125","article-title":"Siglecs in Brain Function and Neurological Disorders","volume":"8","author":"Siddiqui","year":"2019","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwu043","article-title":"Associations of genetic polymorphisms of Siglecs with human diseases","volume":"24","author":"Angata","year":"2014","journal-title":"Glycobiology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1159\/000504323","article-title":"Siglec-14 enhances NLRP3-inflammasome activation in macrophages","volume":"12","author":"Tsai","year":"2020","journal-title":"J Innate Immun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0610-1","article-title":"Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases","volume":"27","author":"Angata","year":"2020","journal-title":"J Biomed Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuag013","article-title":"Role of myeloid cells expressing CD169\/Siglec-1 in host-pathogen interactions","volume":"50","author":"Ronco","year":"2026","journal-title":"FEMS Microbiol Rev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219888110","article-title":"Targeted delivery of lipid antigen to macrophages via the CD169\/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation","volume":"110","author":"Kawasaki","year":"2013","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwu066","article-title":"CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance","volume":"24","author":"Nitschke","year":"2014","journal-title":"Glycobiology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105186","article-title":"Hypoxia\/ischemia impairs CD33 (Siglec-3)\/TREM2 signaling: Potential role in Alzheimer\u2019s pathogenesis","volume":"150","author":"Salminen","year":"2021","journal-title":"Neurochemistry Int"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131853","article-title":"Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus","volume":"211","author":"Ali","year":"2014","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e1010479","DOI":"10.1371\/journal.ppat.1010479","article-title":"CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses","volume":"18","author":"Jandus","year":"2022","journal-title":"PloS Pathog"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2972","article-title":"STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1","volume":"102","author":"Battle","year":"2003","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/ijms25094581","article-title":"\u2018The role of oxygen homeostasis and the HIF-1 factor in the development of neurodegeneration\u2019","volume":"25","author":"Mitroshina","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0256-y","article-title":"IL-6\u2013induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33\u207a myeloma cells","volume":"89","author":"Shamsasenjan","year":"2009","journal-title":"Int J Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1159\/000453214","article-title":"Role of miR-215 in Hirschsprung\u2019s disease pathogenesis by targeting SIGLEC-8","volume":"40","author":"Lei","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1134\/S0026893322030141","article-title":"Mapping regulatory elements within 5\u2032 and 3\u2032 UTRs of SIGLEC15 using a reporter system","volume":"56","author":"Wang","year":"2022","journal-title":"Mol Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/imm.13179","article-title":"DNA methylation\u2013mediated Siglec-7 regulation in natural killer cells via two 5\u2032 promoter CpG sites","volume":"160","author":"Huang","year":"2020","journal-title":"Immunology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35505","article-title":"Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions","volume":"130","author":"Kantarjian","year":"2024","journal-title":"Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102409","article-title":"Emerging antibody-based therapies for the treatment of acute myeloid leukemia","volume":"108","author":"Angenendt","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1073932","article-title":"Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis","volume":"12","author":"Jiang","year":"2023","journal-title":"Front Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0141","article-title":"Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle","volume":"16","author":"Ren","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.11.004","article-title":"Siglecs in immunotherapy: Current clinical landscape and prospects","author":"Purohit","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"B107","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2026.111249","article-title":"Writers and readers of sialylation in immunoregulation in cancer","volume":"302","author":"Decloquement","year":"2026","journal-title":"J Biol Chem"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2024.102503","article-title":"Glycoengineering in antigen-specific immunotherapies","volume":"81","author":"Li","year":"2024","journal-title":"Curr Opin Chem Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:15Z","timestamp":1779342195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2026.1826359"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1826359","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1826359"}}